Episode 126: Pharma and Academia – Dr. Charles Bennett’s Battle

An image of the book: Taking on Big Pharma: Dr. Charles Bennett's Battle

Episode 126: Pharma and Academia – Dr. Charles Bennett’s Battle

In the latest book review, Chadi hosts the authors of the successful expose of his former colleague in “Taking On Big Pharma: Dr. Charles Bennett’s Battle.” Julius Getman and Terri LeClercq share how they met Dr. Bennett on a cruise and became interested in his story about his massive achievements and legal charges against him – mishandling government grant money and violating the False Claims Act. They begin with their reasons for believing that the case against Dr. Bennett was baseless and unfounded, what the actual accusations were, and how he ended up facing off against the pharmaceutical and academic worlds.

Related Resources

Subscribe to Healthcare Unfiltered

Other Episodes You May Enjoy...

Episode 223: From Lab to Statup: Dr. Simrit Parmar on Launching Cellenkos

Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous

Read More

Episode 222: Language Matters: A Patient Perspective

Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those

Read More

Episode 221: Major Progress in Adjuvant Renal Cell Carcinoma

Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease

Read More